MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients

被引:28
作者
Foote, C. J. [1 ]
Greer, W. [1 ]
Kiberd, B. A. [1 ]
Fraser, A. [1 ]
Lawen, J. [1 ]
Nashan, B. [1 ]
Belitsky, P. [1 ]
机构
[1] Dalhousie Univ, Dept Med, Halifax, NS B3H 2Y9, Canada
关键词
D O I
10.1016/j.transproceed.2006.08.120
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Single nucleotide polymorphisms (SNPs) in the multidrug resistance (MDRI) gene correlate with the intestinal function of P-glycoprotein (PGP). PGP serves as a hydrophobic export pump that extrudes cyclosporine (CsA) across the luminal membrane thus preventing CsA absorption. These genetic variants may predict CsA exposure levels in the early posttransplantation period. Methods. CsA absorption profiles were established in 75 renal transplant patients using total daily dose and body weight adjusted 4-hour area under the time-concentration curve, AUC((0-4))/Mg dose/kg body weight, on posttransplant day 3. These patients were subsequently genotyped for C3435T and G2677T polymorphisms using real-time polymerase chain reaction. An analysis was conducted to assess the independent impact of C3435T and G2677T SNPs on CsA bioavailability. Results. C3435T polymorphisms were found to be an independent predictor of CsA AUC((0-4))/mg dose/kg levels on postoperative day 3. An inverse correlation was found between the number of T alleles and AUC values such that every T allele was associated with an approximate 15% decrement in AUC((0-4))/mg dose/kg (P =.034). A similar nonsignificant trend was observed for G2677T polymorphisms. Conclusions. MDR1 SNPs are correlated with CsA exposure in the early post-transplant period. Polymorphisms, in conjunction with other criteria, may become a useful tool to optimize initial drug dosing in renal transplantation.
引用
收藏
页码:2847 / 2849
页数:3
相关论文
共 25 条
  • [21] MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients
    Mai, I
    Störmer, E
    Goldammer, M
    Johne, A
    Krüger, H
    Budde, K
    Roots, I
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (10) : 1101 - 1107
  • [22] C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects
    Min, DI
    Ellingrod, VL
    [J]. THERAPEUTIC DRUG MONITORING, 2002, 24 (03) : 400 - 404
  • [23] Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects
    Nakamura, T
    Sakaeda, T
    Horinouchi, M
    Tamura, T
    Aoyama, N
    Shirakawa, T
    Matsuo, M
    Kasuga, M
    Okumura, K
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (04) : 297 - 303
  • [24] Tanabe M, 2001, J PHARMACOL EXP THER, V297, P1137
  • [25] von Ahsen N, 2001, CLIN CHEM, V47, P1048